New Delhi, Dec 8 (PTI) Glenmark Pharma today said thefirst patient has been dosed in a phase-1 clinical trial ofGBR 1342, an investigational antibody for treatment ofmultiple myeloma.
In May this year, the US health regulator had clearedGlenmark Pharma's investigational new drug application toinitiate phase-1 study of GBR 1342.
GBR 1342 is an investigational new drug from thecompany's immuno-oncology portfolio.
"This first-in-human, open-label study's primaryobjective is to assess the safety and tolerability ofincreasing doses of GBR 1342 in multiple myeloma patientsuntil a maximum tolerated dose is reached," Glenmark Pharmasaid in a BSE filing.
The additional study objectives include assessment ofbiomarkers, immunogenicity and additional measures of anti-tumour activity, it added.
"Glenmark is committed to a new model of drug discoverythat emphasises quality and a highly efficient approach toclinical development, and this milestone for GBR 1342 is anexample of this approach in action," Glenmark PharmaceuticalsPresident and Chief Medical Officer Fred Grossman said.
The stock of Glenmark was trading at Rs 536, up 0.63 percent, on the BSE. PTI SVKABM.
This is unedited, unformatted feed from the Press Trust of India wire.